Govt. of Canada:
Submissions Under Review
This is a list of new drug submissions (NDSs) that are currently being reviewed. These submissions are for drugs containing new active substances, pharmaceuticals and biologics with an active ingredient not approved in Canada. This applies to submissions whose review started on or after April 1, 2015.
Submissions Under Review List:
for systemic use
The bonuses must be tied to something. This, along with progress on 4430 and 7353 would be bonus worthy catalysts. Will know by end of month post CC, JPM and SH Meeting.
This upcoming earnings call may have some surprises with Peramivir via licensing $$$ if the company reached milestones unknown to us...filings in other countries, upgraded approvals in pediatrics, elderly, acute situations.
I don't have specific information but there's been more recent rumblings regarding P on the net.
Front Microbiol. 2016; 7: 450.
Published online 2016 Mar 31
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections
Successful clinical trials and post-marketing data in pediatric populations in Japan support the safety and efficacy of peramivir in this population where administration of other antivirals might not be feasible.
While currently only approved for treatment of uncomplicated influenza in adults, clinical studies and post-marketing efficacy and safety data in pediatric populations provide promise for the potential of approval of peramivir in this highly susceptible population.
The public officials involved in holding up Peramivir should be held liable by the families that suffered injury from the Flu. I just can't let that go and I hope one day someone pursues it with evidence from FOIA data.
Short interest last year at this time:
The lowest short interest last year:
The highest short interest last year:
Haven't seen sub 7 million over the last year: 6,450,499
"Some individuals or government agencies ought to be ashamed of themselves."
And now over 3 years later, after that testimonial , 4430 still has not been brought to market. Some individuals or government agencies ought to be ashamed of themselves.
Nov 12, 2012. Dr. Justin Julander of Utah State University, who coordinates yellow fever testing under the NIAID Program stated, "BCX4430 is an exciting, potential antiviral therapy for the treatment of yellow fever virus infection, for which no approved treatment currently exists. The level of efficacy observed for BCX4430 in these studies compared to other antivirals evaluated against yellow fever is exceptiona
I don't tweet or know how to, nor, do I want to. Yea I listen to my chickens...they give me eggs and fertilizer...and don't talk back.
You're spending too much time listening to the clucks from your chickens, you need to spend more time listening to the tweets from twitterville via: Joe at Drchik23
Hey, hey, hay...you're cutting into my turf. NASDAQ still doesn't have the short interest...2nd time it is late. I need to Kiwi to do the ciphering for me on this one.